Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Suresh K. Durgam net worth and biography

Suresh Durgam Biography and Net Worth

Insider of Intra-Cellular Therapies

Dr. Durgam joined the Company in 2018 as Senior Vice President, Late Stage Clinical Development and Medical Affairs since joining the Company before being promoted as our Chief Medical Officer in October 2020. Dr. Durgam, has over 23 years of experience in clinical research which includes over 17 years in neuropsychiatric drug development, including the development of antipsychotics and antidepressants.

Dr. Durgam served in clinical development leadership roles at Forest Laboratories, Solvay and Allergan plc. He led programs across various indications including major depressive disorder, bipolar mania, bipolar depression, schizophrenia, cognitive impairment associated with schizophrenia, negative symptoms in schizophrenia, anxiety disorders, and pain. He has experience in the U.S. and globally in all phases of drug development from Phase I through Phase 4 studies. In addition to his role in the development of cariprazine and its approval in schizophrenia and bipolar disorder, Dr. Durgam oversaw studies with vilazodone, levomilancipran, and asenapine that led to sNDA fillings and supplemental approvals. He also led the major depressive disorder program with rapastinel and onabotulinumtoxinA for depression.

Dr. Durgam graduated with his medical degree from the Siddhartha Medical College in India and received his residency training in psychiatry at Scott & White Clinic and Hospital – Texas A&M University System College of Medicine.

What is Suresh K. Durgam's net worth?: The estimated net worth of Suresh K. Durgam is at least $1.35 million as of March 7th, 2024. Dr. Durgam owns 16,170 shares of Intra-Cellular Therapies stock worth more than $1,349,387 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Durgam may own. Additionally, Dr. Durgam receives an annual salary of $961,840.00 as Insider at Intra-Cellular Therapies. Learn More about Suresh K. Durgam's net worth.
How old is Suresh K. Durgam?: Dr. Durgam is currently 55 years old. There are 6 older executives and no younger executives at Intra-Cellular Therapies. The oldest executive at Intra-Cellular Therapies is Dr. Robert E. Davis Ph.D., Senior VP & Chief Scientific Officer, who is 73 years old. Learn More on Suresh K. Durgam's age.
What is Suresh K. Durgam's salary?: As the Insider of Intra-Cellular Therapies, Inc., Dr. Durgam earns $961,840.00 per year. There are 3 executives that earn more than Dr. Durgam. The highest earning executive at Intra-Cellular Therapies is Dr. Sharon Mates Ph.D., Co-Founder, Chairman & CEO, who commands a salary of $2,230,000.00 per year. Learn More on Suresh K. Durgam's salary.
How do I contact Suresh K. Durgam?: The corporate mailing address for Dr. Durgam and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Suresh K. Durgam's contact information.
Has Suresh K. Durgam been buying or selling shares of Intra-Cellular Therapies?: Suresh K. Durgam has not been actively trading shares of Intra-Cellular Therapies during the last ninety days. Most recently, Suresh K. Durgam sold 6,450 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $66.56, for a transaction totalling $429,312.00. Following the completion of the sale, the executive vice president now directly owns 16,170 shares of the company's stock, valued at $1,076,275.20. Learn More on Suresh K. Durgam's trading history.
Who are Intra-Cellular Therapies' active insiders?: Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.
Are insiders buying or selling shares of Intra-Cellular Therapies?: During the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 697,694 shares worth more than $49,905,719.27. The most recent insider tranaction occured on December, 4th when CEO Sharon Mates sold 51,000 shares worth more than $4,375,800.00. Insiders at Intra-Cellular Therapies own 2.6% of the company. Learn More about insider trades at Intra-Cellular Therapies.
Information on this page was last updated on 12/4/2024.

Suresh K. Durgam Insider Trading History at Intra-Cellular Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2024	Sell	6,450	$66.56	$429,312.00	16,170
1/2/2024	Sell	62,282	$70.60	$4,397,109.20
12/13/2023	Sell	21,262	$65.00	$1,382,030.00
7/17/2023	Sell	1,842	$65.00	$119,730.00	21,262
3/13/2023	Sell	7,344	$45.04	$330,773.76	23,104
2/24/2023	Sell	7,906	$47.14	$372,688.84	23,104
2/21/2023	Sell	8,354	$46.84	$391,301.36	23,104
3/4/2022	Sell	3,860	$55.52	$214,307.20
3/2/2022	Sell	4,177	$56.98	$238,005.46
2/24/2022	Sell	4,046	$52.27	$211,484.42
2/22/2022	Sell	4,177	$55.29	$230,946.33
1/18/2022	Sell	6,223	$42.03	$261,552.69
1/10/2022	Sell	6,870	$40.76	$280,021.20
2/19/2021	Sell	2,734	$39.25	$107,309.50	25,838
1/11/2021	Sell	4,367	$32.12	$140,268.04	21,851

Suresh K. Durgam Buying and Selling Activity at Intra-Cellular Therapies

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $83.45

$82.76

$85.03

50 Day Range

MA: $83.64

$73.84

$91.57

2 Week Range

Now: $83.45

$62.78

$93.45

Volume

1,120,463 shs

Average Volume

827,488 shs

Market Capitalization

$8.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.

Suresh Durgam Biography and Net Worth

What is Suresh K. Durgam's net worth?

How old is Suresh K. Durgam?

What is Suresh K. Durgam's salary?

How do I contact Suresh K. Durgam?

Has Suresh K. Durgam been buying or selling shares of Intra-Cellular Therapies?

Who are Intra-Cellular Therapies' active insiders?

Are insiders buying or selling shares of Intra-Cellular Therapies?